Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.

Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, Hare CB.

Clin Infect Dis. 2015 Nov 15;61(10):1601-3. doi: 10.1093/cid/civ778. Epub 2015 Sep 1.

2.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team..

Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
25890673
3.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

4.

Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabuddhe VV, Chen J, Lorey TS, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Castle PE.

J Clin Microbiol. 2014 Aug;52(8):2892-7. doi: 10.1128/JCM.03517-13. Epub 2014 Jun 4.

5.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups.; SILCAAT Scientific Committee..

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

6.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group.; ESPRIT Study Group.; SILCAAT Scientific Committee..

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

7.

Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.

Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, Buchbinder S.

PLoS Med. 2014 Mar 4;11(3):e1001613. doi: 10.1371/journal.pmed.1001613. eCollection 2014 Mar. No abstract available.

8.

Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men.

Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabuddhe VV, Luhn P, Gage JC, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Dec 1;208(11):1768-75. doi: 10.1093/infdis/jit374. Epub 2013 Aug 1.

9.

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men.

Sahasrabuddhe VV, Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, Lorey TS, LaMere BJ, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Feb 1;207(3):392-401. doi: 10.1093/infdis/jis694. Epub 2012 Nov 16.

10.

A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men.

Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, Lorey TS, LaMere B, Gage JC, Fetterman B, Darragh TM, Rodriguez AC, Wentzensen N.

Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):42-9. doi: 10.1158/1055-9965.EPI-12-0984. Epub 2012 Nov 15.

11.

Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, Sahasrabuddhe VV, Lamere B, Gage JC, Fetterman B, Darragh TM, Castle PE.

AIDS. 2012 Nov 13;26(17):2185-92. doi: 10.1097/QAD.0b013e328359f255.

12.

Interrater agreement of anal cytology.

Darragh TM, Tokugawa D, Castle PE, Follansbee S, Borgonovo S, LaMere BJ, Schwartz L, Gage JC, Fetterman B, Lorey T, Wentzensen N.

Cancer Cytopathol. 2013 Feb;121(2):72-8. doi: 10.1002/cncy.21218. Epub 2012 Jul 18.

13.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team..

Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
14.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team..

Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
15.

Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics.

Hoover KW, Butler M, Workowski KA, Follansbee S, Gratzer B, Hare CB, Johnston B, Theodore JL, Tao G, Smith BD, Chorba T, Kent CK; Evaluation Group for Adherence to STD and Hepatitis Screening..

Sex Transm Dis. 2012 May;39(5):349-53. doi: 10.1097/OLQ.0b013e318244a923.

PMID:
22504597
16.

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ, Shafer RW.

Antiviral Res. 2011 Dec;92(3):484-7. doi: 10.1016/j.antiviral.2011.09.010. Epub 2011 Oct 4.

17.

A comparison of dacron versus Flocked nylon swabs for anal cytology specimen collection.

Gage JC, Ghosh A, Borgonovo S, Follansbee S, Wentzensen N, Gravitt PE, Grabe N, Lahrmann B, Castle PE.

Acta Cytol. 2011;55(4):364-7. doi: 10.1159/000329488. Epub 2011 Jul 22.

18.

STD screening of HIV-infected MSM in HIV clinics.

Hoover KW, Butler M, Workowski K, Carpio F, Follansbee S, Gratzer B, Hare B, Johnston B, Theodore JL, Wohlfeiler M, Tao G, Brooks JT, Chorba T, Irwin K, Kent CK; Evaluation Group for Adherence to STD and Hepatitis Screening..

Sex Transm Dis. 2010 Dec;37(12):771-6. doi: 10.1097/OLQ.0b013e3181e50058.

PMID:
20585275
19.

Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group.; SILCAAT Scientific Committee., Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.

20.

Increased rates of appendicitis in HIV-infected men: 1991-2005.

Klein DB, Hurley LB, Horberg MA, Silverberg MJ, Follansbee SE, Flamm JA, Green GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):139-40. doi: 10.1097/QAI.0b013e3181b05d52. No abstract available.

PMID:
19704266

Supplemental Content

Loading ...
Support Center